Immunovant Inc（IMVT）资讯与事件IMVTImmunovant Inc

Immunovant Shares Down 6% to $30.05

Shares of Immunovant (IMVT), which has an ongoing Phase 2b Sjogren's disease study, are down 6% to $30.05 in morning trading.

H.C. Wainwright: Roivant IMVT-1402 Development Fails

H.C. Wainwright analyst Douglas Tsao notes that this morning, Roivant Sciences (ROIV) reported that IMVT-1402 missed the Week 12 Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity primary endpoint in a 57-patient cutaneous lupus erythematosus proof-of-concept study and will discontinue development in CLE. While the firm acknowledges this is disappointing, it views it as an indication-specific failure in a biologically complex skin-dominant autoimmune disease. Wainwright remains confident in '1402 in more direct pathogenic-IgG biology, including myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and Graves' disease. The company reiterated to Wainwright that Immunovant (IMVT) - which is majority-owned subsidiary of Roivant - applies a high clinical and competitive bar when deciding which indications to advance, reflecting its focus on capital efficiency. The firm has a Buy rating on Immunovant and a price target of $41 on the shares.

Immunovant Halts IMVT-1402 Development in CLE

Immunovant announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 for the treatment of cutaneous lupus erythematosus, CLE. The study did not achieve statistical significance on its primary endpoint of percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity score at Week 12. Numerical trends favoring IMVT-1402 over placebo were observed across multiple endpoints, and patients who achieved deeper IgG reductions from baseline were more likely to achieve improved clinical responses. However, due to the competitive landscape and the clinical results observed, Immunovant plans to stop development in CLE.